Retrovirology

, 6:P90 | Cite as

P06-01. Developing a sponsor-initiated clinical guidance for AIDS vaccine research

  • F Priddy
  • J Becker
  • J-L Excler
Open Access
Poster presentation
  • 543 Downloads

Keywords

Community Engagement Male Circumcision Study Staff Guidance Document Family Planning Service 

Background

Existing ICH-Good Clinical Practices guidelines provide well established guidance for organizations conducting AIDS vaccine research. However, some important processes related to conduct of clinical studies and issues specific to AIDS vaccine research are not addressed by GCP. We developed an institutional clinical guidance document for research partners discussing essential processes and practices required to conduct IAVI-sponsored research that aims to support adherence to high ethical and quality standards. This guidance document applies to clinical trials and observational and behavioural research studies.

Methods

The document describes practices that have been developed and applied over the past decade of IAVI-sponsored clinical studies. To identify key topics, we reviewed existing guidance from GCP-related documents, the UNAIDS/WHO guidance documents ''Ethical considerations in biomedical HIV prevention trials'' (2007) and ''Good participatory practices for biomedical HIV prevention trials'' (2007), national regulations and guidance documents from other research organizations. A framework and list of key topics was circulated to collaborating investigators and stakeholders for input.

Results

The guidance document currently addresses 17 key topics: community engagement, informed consent and protection of human subjects, HIV VCT, risk reduction counseling, male circumcision, family planning services, sexually transmitted infections, screening and treatment, counselling and referral for HIV-infected individuals, referral for health services, quality assurance/quality improvement for service delivery, laboratory management, vaccine-induced HIV antibodies, treatment and compensation for physical harm, post-exposure prophylaxis (PEP) for study staff, social impact, gender, and post-trial access. Challenges encountered were to use language broad enough to recommend but not require when specific procedures may conflict with local practices or national requirements, and to determine how to effectively disseminate the guidance.

Conclusion

The clinical guidance document communicates expectations for conduct of studies, including processes responsive to the needs of study staff, study volunteers and communities, to clinical research collaborators as well as stakeholders and the larger research community.

Copyright information

© Priddy et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.

Authors and Affiliations

  • F Priddy
    • 1
  • J Becker
    • 1
  • J-L Excler
    • 1
  1. 1.Medical AffairsInternational AIDS Vaccine InitiativeNew YorkUSA

Personalised recommendations